Uncategorized
EyeGate reports increased net loss in second quarter
EyeGate Pharmaceuticals reported a $3.823 million net loss for the second quarter of 2016, compared with a $1.541 million net loss in the second quarter of 2015.The increased loss was primarily due to expenses related to clinical trials of EGP-437 for treatment of anterior uveitis and of EGP-437 for treatment of inflammation and pain after cataract surgery, as well as continued development of EyeGate Ocular Bandage Gel, according to a company press release.